Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BIIB vs ILMN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BIIB Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

BIIB Overall Winner 6-Pillar Tally: BIIB 4 – 2 ILMN Matrix Metrics: BIIB 6 – 4 ILMN

As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Illumina Inc (ILMN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BIIB carries a Unified Composite Score of 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin), whereas ILMN carries 55.1/100 (HOLD) at $200.12 (33.5x Forward P/E, 19.1% operating margin).

  • Composite vs. Pillar Nuance: While ILMN currently prints a higher short-term Unified Composite Score (55.1/100 HOLD vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (23.5% vs. 19.1% operating margin) and revenue trajectory (+10.6% vs. +4.2% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BIIB vs ILMN
BIIB NASDAQ Head-to-Head Winner
Biogen Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$252.72
-0.27% 1D
Market Cap $37.0B
TTM Revenue $10.3B
Forward P/E 15.6x
Beta / 30D Vol 0.27β · 36% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 45.0 Fund 52.0 Flow 64.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.3% over 20 days), RSI 60
RSI-14: 60.3 · SMA20: $250.29 · SMA50: $234.03
ILMN NASDAQ
Illumina Inc
Laboratory Analytical Instruments
$200.12
-3.33% 1D
Market Cap $31.7B
TTM Revenue $4.54B
Forward P/E 33.5x
Beta / 30D Vol 1.34β · 85% Vol
Unified Composite Score
55.1 / 100 HOLD
Tech 53.0 Fund 57.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 33
RSI-14: 33.3 · SMA20: $241.69 · SMA50: $248.68

6-Pillar Scorecard Institutional Category Breakdown (BIIB 4 – 2 ILMN)

Columns: Metric · BIIB · ILMN
1. Valuation Multiples BIIB
Forward P/E 15.6x 33.5x
Trailing P/E 109.9x 36.6x
PEG Ratio 3.45x 2.62x
EV / Revenue 4.2x 7.2x
2. Growth & Scale BIIB
Revenue Growth (YoY) +10.6% +4.2%
Earnings Growth (YoY) -84.8% +45.9%
TTM Revenue (USD) $10.3B $4.54B
Market Cap $37.0B $31.7B
3. Profitability & Quality BIIB
Gross Margin 75.8% 67.7%
Operating Margin 23.5% 19.1%
Net Profit Margin 3.4% 19.7%
Return on Equity (ROE) 1.9% 32.4%
4. Balance Sheet & Cash Flow ILMN
Cash Generation (TTM) $1.64B $1.14B EBITDA
Cash Flow Margin 16.0% 25.2% EBITDA Mgn
Net Cash / Leverage $6.50B Net Debt (0.41x D/E) $1.02B Net Debt (0.74x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BIIB
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 18.4% (6th %ile) 50.0% (24th %ile)
Put/Call OI Skew 0.77x (Call-Skewed) 0.68x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat ILMN
OpEx & R&D Intensity 52.3% of Rev ($5.39B) 48.6% of Rev ($2.21B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Concentrated Oligopoly Moat
Supply-Chain Role Drug Manufacturers - General Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BIIB (6) vs ILMN (4)
Institutional Metric BIIB ILMN Criterion Row Edge
Market Capitalization
Scale
$37.0B $31.7B Larger Scale BIIB
Trailing P/E Ratio
Valuation
109.9x 36.6x Lower Multiple ILMN
Forward P/E Ratio
Valuation
15.6x 33.5x Lower Multiple BIIB
Revenue Growth (YoY)
Growth
+10.6% +4.2% Higher Growth BIIB
Operating Margin (TTM)
Profitability
23.5% 19.1% Higher Margin BIIB
Net Profit Margin
Profitability
3.4% 19.7% Higher Margin ILMN
Return on Equity (ROE)
Capital Efficiency
1.9% 32.4% Higher ROE ILMN
52-Week Range Position
Momentum
92% ($160–$261) 44% ($113–$309) Stronger Trend BIIB
Beta / 30D Volatility
Risk Regime
0.27β · 36% Vol 1.34β · 85% Vol Lower Realized Risk BIIB
Unified Institutional Score
Composite Signal
50.2 / 100 (HOLD) 55.1 / 100 (HOLD) Higher Composite ILMN
Trailing 12M Revenue (USD)
Operating Scale
$10.3B $4.54B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.8% 67.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.45x PEG · 4.2x EV/Rev 2.62x PEG · 7.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.64B ($6.50B Net Debt (0.41x D/E)) $1.14B EBITDA ($1.02B Net Debt (0.74x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BIIB +32.41 pp
BIIB: +8.63% · ILMN: -23.78%
3M Horizon BIIB +12.62 pp
BIIB: +18.9% · ILMN: +6.28%
6M Horizon ILMN +9.73 pp
BIIB: +31.69% · ILMN: +41.42%
1Y Horizon ILMN +13.45 pp
BIIB: +53.41% · ILMN: +66.86%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BIIB Revenue ILMN Revenue BIIB Op. Margin ILMN Op. Margin Margin Leader
FY2018 $13.4B $3.33B 43.8% 26.5% BIIB
FY2019 $14.4B $3.54B 49.0% 27.8% BIIB
FY2020 $13.4B N/A 33.8% N/A BIIB
FY2021 $11.0B $3.24B 25.9% 17.9% BIIB
FY2022 $10.2B $4.53B 29.9% -2.7% BIIB
FY2023 $9.84B $4.50B 11.8% -23.7% BIIB
FY2024 $9.68B $4.37B 16.9% -19.1% BIIB
FY2025 $9.89B $4.34B 13.1% 18.6% ILMN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BIIB CONSOLIDATION
17d in phase · OBV ACCUMULATION
Current IV 18.4%
IV Percentile 6th %ile
Put/Call OI Skew 0.77x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact BIIB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ILMN CONSOLIDATION
81d in phase · OBV DISTRIBUTION
Current IV 50.0%
IV Percentile 24th %ile
Put/Call OI Skew 0.68x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ILMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BIIB Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $37.0B market capitalization and 23.5% operating margin.
OpEx & R&D Reinvestment 52.3% of Rev ($5.39B)
90D Engineering Disclosures 0 Published
ILMN Moat Profile Concentrated Oligopoly Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $31.7B market capitalization and 19.1% operating margin.
OpEx & R&D Reinvestment 48.6% of Rev ($2.21B)
90D Engineering Disclosures 0 Published · Spatial Genomics

Investor FAQ BIIB vs ILMN Key Questions & Quantitative Answers

As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Illumina Inc (ILMN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BIIB carries a Unified Composite Score of 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin), whereas ILMN carries 55.1/100 (HOLD) at $200.12 (33.5x Forward P/E, 19.1% operating margin). Composite vs. Pillar Nuance: While ILMN currently prints a higher short-term Unified Composite Score (55.1/100 HOLD vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (23.5% vs. 19.1% operating margin) and revenue trajectory (+10.6% vs. +4.2% YoY).

BIIB leads the Growth & Scale pillar: BIIB posts +10.6% YoY revenue growth and -84.8% YoY earnings growth on $10.3B TTM revenue (75.8% gross margin, 23.5% operating margin), compared with ILMN at +4.2% YoY revenue growth and +45.9% YoY earnings growth on $4.54B TTM revenue (67.7% gross margin, 19.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BIIB cumulative revenue shifted -26.5% while ILMN shifted +30.3%. In operating R&D and SG&A reinvestment, BIIB deploys 52.3% of Rev ($5.39B) (0 90-day corporate R&D disclosures) versus 48.6% of Rev ($2.21B) (0 disclosures) for ILMN.

BIIB screens cheaper on headline valuation multiples. BIIB trades at 15.6x Forward P/E, 109.9x Trailing P/E, 3.45x PEG, and 4.2x EV/Revenue (16.0% FCF margin), whereas ILMN trades at 33.5x Forward P/E, 36.6x Trailing P/E, 2.62x PEG, and 7.2x EV/Revenue (25.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BIIB (1.9% ROE) versus ILMN (32.4% ROE) capital efficiency.

In options market volatility and institutional positioning, BIIB carries 18.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.27β · 36% Vol realized risk). By comparison, ILMN carries 50.0% implied volatility (24th %ile, Compressed (<25th %ile)), a 0.68x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.34β · 85% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.